Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.41) EPS for the quarter, FiscalAI reports. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The company had revenue of $0.66 million for the quarter.
Xenetic Biosciences Price Performance
Shares of Xenetic Biosciences stock traded down $0.11 during trading on Thursday, hitting $2.85. The company’s stock had a trading volume of 18,955 shares, compared to its average volume of 21,455. The stock has a market cap of $6.53 million, a price-to-earnings ratio of -2.37 and a beta of 2.10. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93. The stock has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.81.
Institutional Trading of Xenetic Biosciences
An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. 15.12% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Check Out Our Latest Report on Xenetic Biosciences
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.
At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.
Featured Articles
- Five stocks we like better than Xenetic Biosciences
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
